Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. [electronic resource]
Producer: 20050919Description: 126-30 p. digitalISSN:- 1527-9995
- Adenocarcinoma -- blood
- Aged
- Aged, 80 and over
- Alopecia -- chemically induced
- Androgen Antagonists -- therapeutic use
- Antineoplastic Agents, Hormonal -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- blood
- Bone Neoplasms -- drug therapy
- Combined Modality Therapy
- Diphosphonates -- administration & dosage
- Disease Progression
- Disease-Free Survival
- Docetaxel
- Drug Resistance, Neoplasm
- Estramustine -- administration & dosage
- Humans
- Imidazoles -- administration & dosage
- Life Tables
- Liver Neoplasms -- drug therapy
- Lung Neoplasms -- drug therapy
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasm Proteins -- blood
- Neutropenia -- chemically induced
- Orchiectomy
- Pain -- drug therapy
- Palliative Care
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- blood
- Radiotherapy, High-Energy
- Remission Induction
- Survival Analysis
- Taxoids -- administration & dosage
- Treatment Outcome
- Zoledronic Acid
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.